8th Biologics Manufacturing Asia 2021

The 8th Annual Biologics Manufacturing Asia 2021 is Asia’s bioprocessing focused, knowledge-sharing conference that provides regional biopharmaceutical industry stakeholders a carefully tailored networking platform for leveraging opportunities for strategic collaboration, and exposure to the latest manufacturing technologies and know-how. We have an agenda built around success stories from Asia’s biopharmas as well as the technical expertise from International Biopharmas and BIG Pharmas, presentations on the latest manufacturing technologies such as single use and continuous processing for biologics, key challenges in cell therapy manufacturing, cost-reduction strategies in downstream processing, sustainability case studies surrounding single use systems, discussions on vaccine manufacturing, know-how on the developments in pathogen safety amongst other crucial themes. In addition, speakers will be exploring cost reduction, process optimization strategies to maintain competitiveness as well as leveraging opportunities for strategic partnerships and in- and out-licensing opportunities. With this edition of Biologics Manufacturing Asia, we have the co-located 5th Annual BioLogistics World Asia conference and the Asia-Pacific Bioprocessing Excellence Awards as well.

Biologics industry in the APAC region is consistently showing a positive progression and is estimated to be the fastest growing market in the world. The key drivers motivating the growth of the biologics industry in Asia are:

- Competitive manufacturing Costs
- New cell-culture engineering and techniques
- Fast-track flexible GMP facilities equipped with disposables
- Increased use of disposables
- Implementation of continuous manufacturing
- Combining modular facilities, single-use and other advances in the downstream processing of biologics

While experiencing excellence in manufacturing processes, the industry is constantly reworking strategies and on the lookout for tools to overcome high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain. Crucial aspects of process and product characterization, analytical method development amongst others support the manufacturing value chain and analytical technologies are being explored. Portfolios are expanding to include heavier emphasis on regenerative medicine, particularly cell and gene therapy.